Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
NCT00799448 · Novo Nordisk A/S · PHASE4 · terminated · last registry update 2017-02-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment status” | – | Registry record, Novo Nordisk A/S |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KCNJ11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-10-26Results posted on the registry: University of Dundee, Gliclazide MR + Sitagliptin (NCT00780715)
- 2017-10-18Phase 3 first posted: Sherief Abd-Elsalam, Cabergoline + Gliclazide (NCT03313661)
- 2017-10-17Results posted on the registry: University of California, San Diego, recombinant human chorionic gonadotropin + Recombinant human follicle stimulating hormone (NCT00989781)
- 2017-10-13Results posted on the registry: National Institute of Mental Health (NIMH), Diazoxide + Placebo (NCT02049385)
- 2017-10-13Also stopped (terminated): National Institute of Mental Health (NIMH), Diazoxide + Placebo (NCT02049385)
- 2017-06-05Results posted on the registry: Arbelaez, Ana Maria, placebo + repaglinide (NCT00763412)
- 2017-04-24Phase 3 first posted: Tehran University of Medical Sciences, Sitagliptin 100mg + Pioglitazone 30 mg (NCT03125694)
- 2017-03-09Phase 3 first posted: Seoul National University Bundang Hospital, Ipragliflozin + Sitagliptin (NCT03076112)
- 2017-02-23Results posted on the registry: Merck Sharp & Dohme LLC, Omarigliptin + Placebo to omarigliptin (NCT01698775)
- 2017-01-24Also stopped (withdrawn): Maja Kovacevic, MD, 5% Topical Minoxidil Solution + 15% Topical Minoxidil Solution (NCT02486848)
- 2016-12-02Also stopped (withdrawn): Disphar International B.V., Gliclazide 120 mg MR Tablets Formula A + Gliclazide 120 mg MR Tablets (NCT02980757)
- 2016-10-14Results posted on the registry: Sanofi, Lixisenatide (AVE0010) + Placebo (NCT01798706)
- 2016-09-02Also stopped (withdrawn): University of Florida, 5% Minoxidil + 200mg Spironolactone (NCT02483195)
- 2016-09-01Also stopped (withdrawn): Essentialis, Inc., 290 mg DCCR + 435 mg DCCR (NCT00973271)
- 2016-09-01Also stopped (withdrawn): Essentialis, Inc., Diazoxide choline + Diazoxide choline high dose (NCT00901823)
- 2016-06-10Results posted on the registry: Boehringer Ingelheim, midazolam + BI 201335 (NCT01525628)
- 2016-05-11Results posted on the registry: Merck Sharp & Dohme LLC, Metformin + Sitagliptin (NCT01709305)
- 2016-04-15Results posted on the registry: Baylor College of Medicine, Exenatide + Glipizide (NCT01951651)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision